Exploring Three High Growth Tech Stocks in the United States

The market in the United States has remained flat over the past week but has seen a significant 32% increase over the past year, with earnings expected to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for continued expansion and innovation in alignment with these promising market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	23.83%	24.32%	★★★★★★
Ardelyx	25.24%	69.64%	★★★★★★
Sarepta Therapeutics	24.00%	42.51%	★★★★★★
Alnylam Pharmaceuticals	22.35%	70.33%	★★★★★★
Clene	78.50%	60.16%	★★★★★★
TG Therapeutics	34.66%	56.98%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 245 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Apellis Pharmaceuticals (NasdaqGS:APLS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and commercializing therapeutic compounds aimed at inhibiting the complement system for treating autoimmune and inflammatory diseases, with a market cap of approximately $4.41 billion.

Operations: Apellis Pharmaceuticals generates revenue primarily from developing and commercializing proprietary therapeutics, totaling $715.22 million. The company is focused on leveraging its expertise in complement system inhibition to treat autoimmune and inflammatory diseases.

Apellis Pharmaceuticals has showcased significant progress, particularly in its innovative treatments for rare kidney diseases. Recent data from the VALIANT study underscored pegcetacoplan's potential, demonstrating a 68% reduction in proteinuria and stabilization of kidney function. This advancement is critical given the high recurrence rates of disease post-kidney transplant. Financially, Apellis reported a substantial increase in revenue to $196.83 million for Q3 2024, up from $110.4 million year-over-year, with losses narrowing significantly to $57.45 million from $140.24 million. These developments suggest a robust trajectory as the company gears up for new drug applications in early 2025, marking significant strides in addressing unmet medical needs within nephrology and beyond.

• Click here to discover the nuances of Apellis Pharmaceuticals with our detailed analytical health report.

• Review our historical performance report to gain insights into Apellis Pharmaceuticals''s past performance.

Cipher Mining (NasdaqGS:CIFR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cipher Mining Inc. focuses on developing and operating industrial-scale bitcoin mining data centers in the United States, with a market capitalization of $2.19 billion.

Operations: Cipher Mining Inc. generates revenue primarily through its data processing segment, amounting to $152.47 million. The company is involved in the operation of industrial-scale bitcoin mining data centers across the United States.

Cipher Mining, an emerging name in the tech sector, is navigating through its growth phase with significant strategic expansions and a focus on enhancing its technological infrastructure. In November 2024, the company reported mining 202 bitcoins while actively deploying 76,000 rigs, highlighting its operational scale. Moreover, Cipher's recent acquisition of the Stingray site in West Texas for $4.1 million underscores its aggressive expansion strategy to boost capacity and efficiency. Financially, despite a net loss of $86.75 million in Q3 2024 reflecting ongoing investments and scaling efforts, Cipher's revenue growth forecast at an impressive rate of 56.6% annually signals robust future prospects if current trends persist. This performance is pivotal as it aligns with industry shifts towards more sustainable and technologically advanced mining solutions.

• Navigate through the intricacies of Cipher Mining with our comprehensive health report here.

• Examine Cipher Mining's past performance report to understand how it has performed in the past.

Cellebrite DI (NasdaqGS:CLBT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cellebrite DI Ltd. develops solutions for legally sanctioned investigations across various regions, including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, with a market cap of $4.44 billion.

Operations: Cellebrite DI generates revenue primarily from its Internet Software & Services segment, amounting to $371.61 million. The company's offerings support legally sanctioned investigations across multiple global regions.

Cellebrite DI is positioning itself as a pivotal player in the tech landscape, particularly through its recent integration with RelativityOne, enhancing mobile data management efficiency—a critical component in today’s digital forensic and legal sectors. This move, combined with an anticipated annual profit growth of 83.9%, underscores its strategic focus on innovation and market adaptation. Despite facing profitability challenges, Cellebrite's R&D investment remains robust, aligning with its revenue which is expected to grow by 14% annually. These developments come at a time when the company navigates executive transitions, aiming to sustain momentum under new leadership while expanding its technological footprint in a competitive industry.

• Dive into the specifics of Cellebrite DI here with our thorough health report.

• Understand Cellebrite DI's track record by examining our Past report.

Next Steps

• Click here to access our complete index of 245 US High Growth Tech and AI Stocks.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com